AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of AnaptysBio in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will post earnings of ($1.44) per share for the quarter. HC Wainwright has a "Neutral" rating and a $19.00 price target on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.02) per share. HC Wainwright also issued estimates for AnaptysBio's Q2 2025 earnings at ($1.52) EPS, Q3 2025 earnings at ($1.61) EPS and Q4 2025 earnings at ($1.70) EPS.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million.
ANAB has been the topic of several other research reports. Truist Financial lifted their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. BTIG Research lowered shares of AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Wedbush restated an "outperform" rating and issued a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $75.00 to $66.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company dropped their price target on shares of AnaptysBio from $56.00 to $40.00 and set an "overweight" rating for the company in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.09.
View Our Latest Analysis on AnaptysBio
AnaptysBio Stock Up 3.7 %
Shares of ANAB traded up $0.56 during trading hours on Friday, reaching $15.58. 187,061 shares of the company traded hands, compared to its average volume of 378,905. The stock's fifty day moving average is $25.93 and its 200 day moving average is $29.48. AnaptysBio has a 1-year low of $14.20 and a 1-year high of $41.31.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. bought a new position in AnaptysBio in the 3rd quarter valued at $49,000. nVerses Capital LLC lifted its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 1,400 shares during the period. Headlands Technologies LLC boosted its holdings in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 2,600 shares during the period. Finally, Point72 DIFC Ltd raised its holdings in AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 5,342 shares during the last quarter.
Insider Activity at AnaptysBio
In other news, insider Paul F. Lizzul sold 1,500 shares of the firm's stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now directly owns 7,020 shares of the company's stock, valued at $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last three months. Corporate insiders own 33.70% of the company's stock.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Featured Articles
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.